Invited commentary.
Carrier
Michel
M
Department of Surgery, Montreal Heart Institute, Montreal, PQ, H1T 1C8, Canada. michel.carrier@icm-mhi.org
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D015415:Biomarkers; D002097:C-Reactive Protein / Q000032:analysis; D002316:Cardiotonic Agents / Q000627:therapeutic use; D015897:Comorbidity; D001026:Coronary Artery Bypass / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy; D008297:Male; D009203:Myocardial Infarction / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control; D011183:Postoperative Complications / Q000097:blood / Q000453:epidemiology* / Q000517:prevention & control; D011292:Premedication; D011300:Preoperative Care; D011446:Prospective Studies; D018570:Risk Assessment; D015983:Selection Bias; D018746:Systemic Inflammatory Response Syndrome / Q000517:prevention & control; D020107:Troponin T / Q000097:blood*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015415:Biomarkers; D002316:Cardiotonic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D020107:Troponin T; D002097:C-Reactive Protein